Protective Efficacy and Immunogenicity of Escherichia Coli K13 Diphtheria Toxoid Conjugate Against Experimental Ascending Pyelonephritis

Overview

Journal Med Microbiol Immunol

Specialty Allergy & Immunology

Date 2005 May 24

PMID 15909203

Citations 5

Authors

Varinder Kumar

N K Ganguly

Kusum Joshi

Rahul Mittal

Kusum Harjai

Sanjay Chhibber

Saroj Sharma

Affiliations

Soon will be listed here.

Abstract

In the present study, protective efficacy of Escherichia coli capsular antigen, K13, was evaluated in a mouse model of pyelonephritis. Unconjugated capsular polysaccharide failed to provide any protection. However, coupling of K13 to diphtheria toxoid (DT) enhanced its immunogenicity and led to significant production of anticapsular antibodies in mice. Immunization of animals with K13-DT conjugate also caused significant improvement in cell-mediated immune response as indicated by an increase in lymphoblastogenic response and in the CD4+/CD8+ cell ratio of splenic lymphocytes. Significant decrease in bacterial load and renal severity scores were observed in K13-DT immunized animals. Suitability of K13-DT conjugate as an effective vaccine candidate against urinary tract infections caused by E. coli has been discussed.

Citing Articles

Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections.

Loubet P, Ranfaing J, Dinh A, Dunyach-Remy C, Bernard L, Bruyere F Front Microbiol. 2020; 11:1509.

PMID: 32719668 PMC: 7350282. DOI: 10.3389/fmicb.2020.01509.

Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

OBrien V, Hannan T, Nielsen H, Hultgren S Microbiol Spectr. 2016; 4(1).

PMID: 26999391 PMC: 4887100. DOI: 10.1128/microbiolspec.UTI-0013-2012.

Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Brumbaugh A, Mobley H Expert Rev Vaccines. 2012; 11(6):663-76.

PMID: 22873125 PMC: 3498450. DOI: 10.1586/erv.12.36.

Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development.

He Y, Xiang Z, Mobley H J Biomed Biotechnol. 2010; 2010:297505.

PMID: 20671958 PMC: 2910479. DOI: 10.1155/2010/297505.

Mucosal immunization with iron receptor antigens protects against urinary tract infection.

Alteri C, Hagan E, Sivick K, Smith S, Mobley H PLoS Pathog. 2009; 5(9):e1000586.

PMID: 19806177 PMC: 2736566. DOI: 10.1371/journal.ppat.1000586.

References

Raksha R, Srinivasa H, Macaden R . Occurrence and characterisation of uropathogenic Escherichia coli in urinary tract infections. Indian J Med Microbiol. 2007; 21(2):102-7. View

Kaijser B, Larsson P, NIMMICH W, Soderstrom T . Antibodies to Escherichia coli K and O antigens in protection against acute pyelonephritis. Prog Allergy. 1983; 33:275-88. DOI: 10.1159/000318336. View

Jansen W, Snippe H . Short-chain oligosaccharide protein conjugates as experimental pneumococcal vaccines. Indian J Med Res. 2004; 119 Suppl:7-12. View

Schneerson R, Robbins J, Parke Jr J, Bell C, Schlesselman J, Sutton A . Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun. 1986; 52(2):519-28. PMC: 261031. DOI: 10.1128/iai.52.2.519-528.1986. View

Lockhart S . Conjugate vaccines. Expert Rev Vaccines. 2004; 2(5):633-48. DOI: 10.1586/14760584.2.5.633. View

Devi S, Zollinger W, Snoy P, Tai J, Costantini P, Norelli F . Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Infect Immun. 1997; 65(3):1045-52. PMC: 175086. DOI: 10.1128/IAI.65.3.1045-1052.1997. View

Ahlstedt S, Hagberg M, Jodal U, Marild S . Cell-mediated immune parameters in children with pyelonephritis caused by Escherichia coli. Prog Allergy. 1983; 33:289-97. DOI: 10.1159/000318337. View

Melegaro A, Edmunds W . The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol. 2004; 19(4):365-75. DOI: 10.1023/b:ejep.0000024752.48929.bd. View

Hekker T, Groeneveld A, Simoons-Smit A, de Man P, Connell H, MACLAREN D . Role of bacterial virulence factors and host factors in the outcome of Escherichia coli bacteraemia. Eur J Clin Microbiol Infect Dis. 2000; 19(4):312-6. DOI: 10.1007/s100960050483. View

10.

Taylor C, Roberts I . Capsular polysaccharides and their role in virulence. Contrib Microbiol. 2004; 12:55-66. DOI: 10.1159/000081689. View

11.

Williams D, Schaeffer A . Current concepts in urinary tract infections. Minerva Urol Nefrol. 2004; 56(1):15-31. View

12.

Burton K . A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J. 1956; 62(2):315-23. PMC: 1215910. DOI: 10.1042/bj0620315. View

13.

Baraldo K, Mori E, Bartoloni A, Petracca R, Giannozzi A, Norelli F . N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines. Infect Immun. 2004; 72(8):4884-7. PMC: 470654. DOI: 10.1128/IAI.72.8.4884-4887.2004. View

14.

Miller T, Marshall E, Nelson J . Infection-induced immunosuppression in pyelonephritis: characteristics of the suppressor cell(s). Kidney Int. 1983; 24(3):313-22. DOI: 10.1038/ki.1983.160. View

15.

Rahn A, Beis K, Naismith J, Whitfield C . A novel outer membrane protein, Wzi, is involved in surface assembly of the Escherichia coli K30 group 1 capsule. J Bacteriol. 2003; 185(19):5882-90. PMC: 193962. DOI: 10.1128/JB.185.19.5882-5890.2003. View

16.

Nickol A, Bonventre P . Visceral leishmaniasis in congenic mice of susceptible and resistant phenotypes: T-lymphocyte-mediated immunosuppression. Infect Immun. 1985; 50(1):169-74. PMC: 262152. DOI: 10.1128/iai.50.1.169-174.1985. View

17.

Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo M, Rodriguez M, Heynngnezz L . A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science. 2004; 305(5683):522-5. DOI: 10.1126/science.1095209. View

18.

Sharma S, Kaur R, Yadav V, Harjai K, Joshi K . Contribution of exotoxin A of Pseudomonas aeruginosa in acute and chronic experimental renal infection. Jpn J Infect Dis. 2004; 57(3):119-20. View

19.

Mittal R, Chhibber S, Sharma S, Harjai K . Macrophage inflammatory protein-2, neutrophil recruitment and bacterial persistence in an experimental mouse model of urinary tract infection. Microbes Infect. 2004; 6(14):1326-32. DOI: 10.1016/j.micinf.2004.08.008. View

20.

Burns S, Hull S . Loss of resistance to ingestion and phagocytic killing by O(-) and K(-) mutants of a uropathogenic Escherichia coli O75:K5 strain. Infect Immun. 1999; 67(8):3757-62. PMC: 96650. DOI: 10.1128/IAI.67.8.3757-3762.1999. View